BioXcel Therapeutics Announces Completion of Pre-NDA Meeting with FDA for BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorders

    NEXT STORY
    Calithera to Participate in Jefferies Virtual Healthcare Conference and SVB Leerink Oncology 1×1 Day
    PREV STORY
    PolyPid Ltd. Provides Corporate Update and Reports Third Quarter 2020 Financial Results
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Henry Ford Health System to Present Webinar on Positive Clinical Impact of T2 Biosystems’ T2Candida® Panel

    LEXINGTON, Mass., May 19, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc., (NASDAQ:TTOO), a company ...

    author_avatar
    NASDAQ Market News

    Aptose to Present Early CG-806 Clinical Findings at the 25th Congress of the European Hematology Association

    author_avatar
    NASDAQ Market News

    OTC/DTC Infectious Disease Diagnostics to 2024: Global Industry Overview, Market Size & Trends, Recent Developments, Profiles of Key Players

    author_avatar
    NASDAQ Market News